Varian said that xoma plans on collecting results for all poc's before they decide which indication to pursue, if any. clearly, xoma is following the lead of anakinra carved through the mountainous terrains in search of an indication they will work on. For example, in regards acne vulgaris:
"The TNF-a inhibitor infliximab and anakinra are investigational drugs in these severe forms and show promising effects"
Maybe the question is what if one or more of the poc's shows enough promise to continue? What should xoma do? Will xoma really put a promising indication on the backburner when they are so starved for revenue?
- - - - - - - - - - - - - - - - - - - - - -
On the 11/07/2012 audio varian estimated poc #3 would be announced in 4-6 weeks which puts the announcement between 12/5 and 12/19, so within the next 2 weeks we should find out what the mystery is.
Did you hear in the same audio Varian mentioned aceon had sales of $150M outside the u.s.? Varian also said that it is a relatively new product which is showing good sales growth.
Xoma should get aceon combination approval (assuming 12 months review period) by the beginning of 2014. Xoma has enough cash to get through 2014. Xoma should muster more cash [than present aceon figures) all through 2014.
In the same audio, Varian estimates tests of xmeta, and xmets should be complete with higher animals in 12-18 months which puts us at the latest of mid 2014. xmetd should also be ready for beginning trials by mid 2014. Hopefully, xoma can auction license/development agreements before the end of 2014.